Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Operating Leases (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Operating Leases data on record, last reported at $583000.0 in Q4 2025.

  • For Q4 2025, Operating Leases changed 0.0% year-over-year to $583000.0; the TTM value through Dec 2025 reached $583000.0, changed 0.0%, while the annual FY2025 figure was $583000.0, 0.0% changed from the prior year.
  • Operating Leases reached $583000.0 in Q4 2025 per VRCA's latest filing, down from $665000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.6 million in Q1 2021 and bottomed at $416000.0 in Q2 2025.
  • Average Operating Leases over 5 years is $1.0 million, with a median of $1.0 million recorded in 2023.
  • The widest YoY moves for Operating Leases: up 0.0% in 2025, down 44.09% in 2025.
  • A 5-year view of Operating Leases shows it stood at $1.4 million in 2021, then fell by 15.18% to $1.2 million in 2022, then decreased by 25.96% to $910000.0 in 2023, then crashed by 35.93% to $583000.0 in 2024, then changed by 0.0% to $583000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $583000.0 in Q4 2025, $665000.0 in Q3 2025, and $416000.0 in Q2 2025.